Several ADCs are under investigation in pre-clinical and clinical settings; among them, B cell maturation antigen (BCMA)-directed ADCs are showing promising effect due to the high and unique expression of BCMA on MM and late memory B cells, and to the oncogenic role of BCMA/APRIL pathway in the disease (56, 58, 59). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.